Evidence map›Paper›PMID 42587415›Full record

ArticleMicrobiologyOpen2026

Universal-Bac

Emanuela Peluso, Sebastião van Uden, Sonja Visentin, Paola Petrini, Daniela Peneda Pacheco, Livia Visai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emanuela PelusoMolecular Medicine Department (DMM), Centre for Health Technologies (CHT), Unità di Ricerca (UdR) INSTM, Operative Unit (OU) of the Interuniversity Center for the Promotion of the 3Rs Principles in Teaching and Research (Centro 3R), University of Pavia, Pavia, Italy.ORCID https://orcid.org/0009-0009-2882-1613
Sebastião van UdenBac3Gel® Lda, Edifício Inovação II, Porto, Salvo, Portugal.ORCID https://orcid.org/0000-0001-9031-2371
Sonja VisentinDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.ORCID https://orcid.org/0000-0001-7262-6166
Paola PetriniBioAvatar Lab, Department of Chemistry, Materials, and Chemical Engineering "G. Natta", Politecnico di Milano, Milan, Italy.ORCID https://orcid.org/0000-0002-5081-5254
Daniela Peneda PachecoBac3Gel® Lda, Edifício Inovação II, Porto, Salvo, Portugal.ORCID https://orcid.org/0000-0003-3735-2432
Livia VisaiMolecular Medicine Department (DMM), Centre for Health Technologies (CHT), Unità di Ricerca (UdR) INSTM, Operative Unit (OU) of the Interuniversity Center for the Promotion of the 3Rs Principles in Teaching and Research (Centro 3R), University of Pavia, Pavia, Italy.ORCID https://orcid.org/0000-0003-1181-3632

Funding

HORIZON-EIC-2023-ACCELERATOROPEN-01 190135075Italian Ministry of University and Research (MUR)
6 · The paper itself

Abstract

Human microbiota is increasingly considered to shape health and disease, drawing interest of pharma and biotech industries in advanced models of in vitro human microbiome to streamline drug development. In this context, Universal-Bac

Indexed as

BiofilmsAnti-Bacterial AgentsHumansMicroscopy, ConfocalStaphylococcus aureusAnti-Bacterial Agents3D culturesantimicrobial resistancebiofilm‐relevant environmentESKAPE pathogensgradientsmicrobial ecologytranslational model

Identifiers

PMID42587415
PMCPMC13469185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.